Results from CADENCE, the first and largest multinational prospective registry for patients with CAD/CAS, describe safety events observed in patients treated with sutimlimab, with an average treatment ...
OWENS CROSS ROADS, Ala. (WAFF) - The City of Owens Cross Roads released a statement addressing the Pathway facility. Owens Cross Roads City Council voted in November to pursue legal action toward the ...
A rare and life-threatening kidney disease in children finally has an effective therapy, thanks in large part to pioneering research and clinical leadership from University of Iowa Health Care Stead ...
Omeros Corporation has surged after out-licensing zaltenibart to Novo Nordisk, securing $340 million upfront and near-term milestones, with potential for $2.1 billion in additional payments. The deal ...
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
Nov 12 (Reuters) - Clearlake Capital Group said on Wednesday it will buy investment manager Pathway Capital Management, as the buyout firm looks to expand its presence in the red-hot private markets ...
– Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB silencing – – Phase 2 studies are ongoing to assess the ...
Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...
The objective of this study was to evaluate the methodology to establish the hemolytic activity of alternative complement pathway as an indicator of the innate immunity in Brazilian fish pacu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback